CINACALCET (SENSIPAR) Calcimimetic Agents in CKD | ESRD | Dialysis and Hemodialysis Patients

Patients with chronic kidney disease have special issues in regulating mineral metabolism.
The kidneys actively hold onto necessary minerals and excrete or get rid of minerals thought to be in excessive supply. Some of these minerals necessary for cellular functions include sodium, potassium, calcium and phosphorous.

The kidneys play a unique role in calcium regulation due to the fact that healthy kidneys activate a form of Vitamin D. Vitamin D in turn facilitates absorption of Calcium from the intestines from the food or from bones.

Other important glands in this metabolic system are the parathyroids. These small glands in the neck secrete a hormone called PTH or parathyroid hormone that boosts the absorption of calcium from the intestine or bones if the body is deemed to have too little calcium.

Patients with abnormal, or scarred kidneys do not make sufficient active Vitamin D. Chronic kidney disease (CKD) patients or end stage renal disease (ESRD) patients therefore may be deficient in calcium and have an elevated parathyroid level. This elevated PTH level is called secondary hyperparathyrodism.

There are several methods of helping to control mineral metabolism in ESRD and CKD patients. Some of these methods include diet, Vitamin D supplementation and drugs which help absorb excessive minerals from the intestine. A relatively new medication acts to help decrease parathyroid hormone production by making the parathyroid gland more sensitive to calcium. This new class of medication is called a calcimimetic because it mimics the effects of calcium on the parathyroid glands.

The articles reference below discuss calcimemetics in CKD and ESRD.

Author Interview: David M. Spiegel, MD, FACP

A Computerized Treatment Algorithm Trial to Optimize Mineral Metabolism in ESRD

David M. Spiegel, Lesley McPhatter, Ann Allison, Joanne C. Drumheller, and Robert Lockridge

CJASN CJN.08170811; published ahead of print February 2012 doi:10.2215/CJN.08170811

Author Interview: Ryota Ikee, MD
Potential influence of sevelamer hydrochloride on responsiveness to erythropoiesis-stimulating agents in haemodialysis patients.

Ikee R, Tsunoda M, Sasaki N, Sato N, Hashimoto N.

Nephrology (Carlton). 2011 Nov 24.
doi: 10.1111/j.1440-1797.2011.01545.x.

Author Interview: Charles M. Henley

Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD


Gerald Miller, James Davis, Edward Shatzen, Matthew Colloton, David Martin, and Charles M. Henley
Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA
Nephrol. Dial. Transplant.
first published online October 29, 2011 doi:10.1093/ndt/gfr589


Author Interview:
J. Andrew Lee, PhD, ScM
A Study of the Association between Cinacalcet Adherence and Biochemical Outcomes


Abstract: [TH-PO263]

Andrew Lee, PhD, Vasily Belozeroff, PhD, Richard Mutell, T. Christopher Bond, PhD, William G. Goodman, MD. Amgen Inc; DaVita Clinical Research.

Author Interview: Dr. Jesús Montenegro

Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.

Montenegro J, Cornago I, Gallardo I, García-Ledesma P, Hernando A, Martinez I, Muñoz RI, Romero MA.
Servicio de Nefrología, Hospital de Galdakao-Usansolo, Galdakao, Vizcaya, Spain.
Nephrology (Carlton). 2011 Oct 25. doi: 10.1111/j.1440-1797.2011.01530.x.

Author Interview: Dr. Giuseppe Cianciolo

VDR Expression on Circulating Endothelial Progenitor Cells in Dialysis Patients Is Modulated by 25(OH)D Serum Levels and Calcitriol Therapy.
Cianciolo G, La Manna G, Cappuccilli ML, Lanci N, Della Bella E, Cuna V, Dormi A, Todeschini P, Donati G, Alviano F, Costa R, Bagnara GP, Stefoni S.
Nephrology Dialysis and Renal Transplantation Unit, S. Orsola University Hospital, Bologna, Italy.
Blood Purif. 2011 Jul 9;32(3):161-173.

Author Interview: Dr. Christopher Chan, MD

Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.

Battistella M, Richardson RM, Bargman JM, Chan CT.
Division of Nephrology, Department of Medicine, University Health Network, Toronto, ON, Canada.
Clin Nephrol. 2011 Aug;76(2):99-103.

Sensipar(R) Patents Upheld By District Court
Injunction Prohibits Teva and Barr from Marketing Generic Versions of Amgen's Sensipar Through 2018 Patent Expiry

THOUSAND OAKS, Calif., Jan. 7, 2011

A U.S. District Court in Delaware today granted an injunction preventing Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and Barr Laboratories, Inc. from commercializing generic versions of Amgen's (Nasdaq: AMGN) Sensipar(R) (cinacalcet) until expiration of the drug's U.S. patents. The latest Sensipar expiry is in 2018. Sensipar is approved for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis and for the treatment of elevated levels of calcium in patients with parathyroid carcinoma.

Comparative Effectiveness of Paricalcitol versus Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis.

Nephron Clin Pract. 2010 Aug 10;117(2):c151-c159.

Schumock GT, et al
Center for Pharmacoeconomic Research, Department of Pharmacy Practice, and Department of Pharmacy Administration, University of Illinois at Chicago, Chicago, Ill.

Calcimimetic Agents in CKD ESRD Dialysis and Hemodialysis Patients

CINACALCET (SENSIPAR) USE INTO A PARICALCITOL (ZEMPLAR) PROTOCOL IN SECONDARY HYPERPARATHYROIDISM
Barbara Clark, Bruno Lima, Piyush Lohiya, Dept of Nephrology,
Allegheny General Hospital, Pittsburgh, PA, USA 
Abstract presented at the National Kidney Foundation Spring Clinical Meeting 2010

Sensipar (Cinacalcet) is made by Amgen. The Sensipar website has a number of educational resource, including prescribing and safety information.

Cinacalcet Decreases Bone Formation Rate in Hypercalcemic Hyperparathyroidism after Kidney Transplantation.

Am J Nephrol. 2010 Apr 30;31(6):482-489.
Borchhardt KA, Diarra D, Sulzbacher I, Benesch T, Haas M, Sunder-Plassmann G.
Division of Nephrology and Dialysis, Department of Medicine III, Medical University Vienna, Vienna, Austria.

Abstract: Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet.

J Nephrology. 2010 May 2. pii: 8E39C3E1-CF8D-4F2A-94D3-D72F4B99DFFC.
Guerra R, Auyanet I, Fernández EJ, Pérez MA, Bosch E, Ramírez A, Suria S, Checa MD.
Department of Nephrology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria - Spain.

Calcimimetic inhibits late-stage cyst growth in ADPKD.

Journal of the American Society of Nephrology. 2009 Jul;20(7):1527-32.
Gattone VH 2nd, Chen NX, Sinders RM, Seifert MF, Duan D, Martin D, Henley C, Moe SM.
Department of Anatomy and Cell Biology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, Indiana 46202, USA. vgattone@iupui.edu
Comment in:

  • J Am Soc Nephrol. 2009 Jul;20(7):1421-5.

 

 

 

 

 


 
 
 
tags and keywords:Hemodialysis, Hemodialysis Patients, Hemodialysis nurses, Hemodialysis Technician, kidney disease, dialysis, hemo dialysis, chronic kidney disease, salt and kidney disease,kidney failure,Hemodialysis treatment, Hemodialysis complications, home Hemodialysis, nocturnal Hemodialysis, renal diet, diets for chronic kidney disease, dialysis diets, kidney diet, CKD, stages of kidney disease, kidney transplantation, necessity for Hemodialysis, Hemodialysis suppliers, Hemodialysis providers, Hemodialysis units, kidney swap, polycystic kidney disease, PKD, ESRD networks, anemia, iron, hepcidin, mortality in Hemodialysis, diabetes, NSF, NSD, Gadolinium, Omniscan, dialysis fistula, dialysis grafts, KDOQI ,KDIGO, peritoneal dialysis, PD dialysis. BNP,MDRD, CKD, ESRD, CKD-EPI, stent grafts for dialysis, dialysis treatments, mortality in Hemodialysis patients

 
 
 

For Advertising Information, please contact info@Hemodialysis.com

Follow Hemodialysis_co on Twitter 
Contact Hemodialysis.com
NKF News
Nephrology Job Board
JobOffers.com | Jobs in
Dialysis & Hemodialysis
Event Calendar: Hemodialysis and Kidney Disease

Five Things Dialysis, Kidney Disease & Hemodialysis Patients and Providers Should Question

Subscribe to the Free Hemodialysis.com Newsletter
Medical Disclaimer: Please Read
Contact email: info@Hemodialysis.com
 
Hemodialysis.com Thanks you for visiting!
Follow Hemodialysis_co on Twitter
 

Subscribe to the Free Hemodialysis.com Newsletter Privacy Policy Advertising Policy Hemodialysis.com
Mission Statement
 

The information on Hemodialysis is for informational purposes only and is not intended as specific medical advice or to be a substitute for medical advice from your physician or health care provider.
Please check with a physician if you need a diagnosis and/or for treatments as well as information regarding your specific condition.
Please read Medical Disclaimer as term of condition for usage of this website.
If you are experiencing urgent medical conditions, call 9-1-1
____________________________________________________
Hemodialysis.com Editor: Marie Benz, MD
info@hemodialysis.com

President: Robert L. Benz, MD FACP
Copyright 2013  Eminent Domains IncAll Rights Reserved.
Our Success is Linked to Yours®

Contact email: info@Hemodialysis.com